TY - JOUR AU - Garbe, C. AU - Leiter, U. PY - 2009 DA - 2009// TI - Melanoma epidemiology and trends JO - Clin Dermatol VL - 27 UR - https://doi.org/10.1016/j.clindermatol.2008.09.001 DO - 10.1016/j.clindermatol.2008.09.001 ID - Garbe2009 ER - TY - JOUR AU - Garbe, C. AU - Eigentler, T. K. AU - Keilholz, U. PY - 2011 DA - 2011// TI - Systematic review of medical treatment in melanoma: current status and future prospects JO - Oncologist VL - 16 UR - https://doi.org/10.1634/theoncologist.2010-0190 DO - 10.1634/theoncologist.2010-0190 ID - Garbe2011 ER - TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. PY - 2011 DA - 2011// TI - Improved survival with vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - JOUR AU - Flaherty, K. T. AU - Robert, C. AU - Hersey, P. PY - 2012 DA - 2012// TI - Improved survival with MEK inhibition in BRAF-mutated melanoma JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1203421 DO - 10.1056/NEJMoa1203421 ID - Flaherty2012 ER - TY - JOUR AU - Hauschild, A. AU - Grob, J. J. AU - Demidov, L. V. PY - 2012 DA - 2012// TI - Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial JO - Lancet VL - 380 UR - https://doi.org/10.1016/S0140-6736(12)60868-X DO - 10.1016/S0140-6736(12)60868-X ID - Hauschild2012 ER - TY - JOUR AU - Hodi, F. S. AU - O'Day, S. J. AU - McDermott, D. F. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Wolchok, J. D. AU - Weber, J. S. AU - Maio, M. PY - 2013 DA - 2013// TI - Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt161 DO - 10.1093/annonc/mdt161 ID - Wolchok2013 ER - TY - STD TI - ZELBORAF Prescribing Information (USPI, United States Product Insert), in, 2011 ID - ref8 ER - TY - STD TI - TAFINLAR Prescribing Information (USPI, United States Product Insert), in, 2014 ID - ref9 ER - TY - JOUR AU - Anforth, R. M. AU - Blumetti, T. C. AU - Kefford, R. F. PY - 2012 DA - 2012// TI - Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma JO - Br J Dermatol VL - 167 UR - https://doi.org/10.1111/j.1365-2133.2012.11155.x DO - 10.1111/j.1365-2133.2012.11155.x ID - Anforth2012 ER - TY - JOUR AU - Kefford, R. AU - Arkenau, H. AU - Brown, M. P. PY - 2010 DA - 2010// TI - Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/jco.2010.28.15_suppl.8503 DO - 10.1200/jco.2010.28.15_suppl.8503 ID - Kefford2010 ER - TY - STD TI - Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011;29:8509. ID - ref12 ER - TY - JOUR AU - Clausen, O. P. AU - Aass, H. C. AU - Beigi, M. PY - 2006 DA - 2006// TI - Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization JO - J Invest Dermatol VL - 126 UR - https://doi.org/10.1038/sj.jid.5700375 DO - 10.1038/sj.jid.5700375 ID - Clausen2006 ER - TY - JOUR AU - Glogau, R. G. PY - 2000 DA - 2000// TI - The risk of progression to invasive disease JO - J Am Acad Dermatol VL - 42 UR - https://doi.org/10.1067/mjd.2000.103339 DO - 10.1067/mjd.2000.103339 ID - Glogau2000 ER - TY - JOUR AU - Ledo, E. PY - 1992 DA - 1992// TI - Wart, keratoacanthoma, and squamous cell carcinoma: a spectrum of the same neoplastic process? JO - Int J Dermatol VL - 31 UR - https://doi.org/10.1111/j.1365-4362.1992.tb04240.x DO - 10.1111/j.1365-4362.1992.tb04240.x ID - Ledo1992 ER - TY - JOUR AU - Cribier, B. AU - Asch, P. AU - Grosshans, E. PY - 1999 DA - 1999// TI - Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases JO - Dermatology VL - 199 UR - https://doi.org/10.1159/000018276 DO - 10.1159/000018276 ID - Cribier1999 ER - TY - JOUR AU - Hodak, E. AU - Jones, R. E. AU - Ackerman, A. B. PY - 1993 DA - 1993// TI - Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases JO - Am J Dermatopathol VL - 15 UR - https://doi.org/10.1097/00000372-199308000-00007 DO - 10.1097/00000372-199308000-00007 ID - Hodak1993 ER - TY - JOUR AU - Magalhaes, R. F. AU - Cruvinel, G. T. AU - Cintra, G. F. PY - 2008 DA - 2008// TI - Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases JO - J Cutan Med Surg VL - 12 UR - https://doi.org/10.2310/7750.2008.07042 DO - 10.2310/7750.2008.07042 ID - Magalhaes2008 ER - TY - JOUR AU - Patel, A. AU - Halliday, G. M. AU - Cooke, B. E. PY - 1994 DA - 1994// TI - Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma JO - Br J Dermatol VL - 131 UR - https://doi.org/10.1111/j.1365-2133.1994.tb08580.x DO - 10.1111/j.1365-2133.1994.tb08580.x ID - Patel1994 ER - TY - JOUR AU - Goldenhersh, M. A. AU - Olsen, T. G. PY - 1984 DA - 1984// TI - Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma JO - J Am Acad Dermatol VL - 10 UR - https://doi.org/10.1016/S0190-9622(84)80010-9 DO - 10.1016/S0190-9622(84)80010-9 ID - Goldenhersh1984 ER - TY - JOUR AU - Gjerstorff, M. L. PY - 2011 DA - 2011// TI - The Danish Cancer Registry JO - Scand J Public Health VL - 39 UR - https://doi.org/10.1177/1403494810393562 DO - 10.1177/1403494810393562 ID - Gjerstorff2011 ER - TY - JOUR AU - Storm, H. H. AU - Michelsen, E. V. AU - Clemmensen, I. H. PY - 1997 DA - 1997// TI - The Danish Cancer Registry--history, content, quality and use JO - Dan Med Bull VL - 44 ID - Storm1997 ER - TY - JOUR AU - Erichsen, R. AU - Lash, T. L. AU - Hamilton-Dutoit, S. J. PY - 2010 DA - 2010// TI - Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank JO - Clin Epidemiol VL - 2 UR - https://doi.org/10.2147/CLEP.S9908 DO - 10.2147/CLEP.S9908 ID - Erichsen2010 ER - TY - JOUR AU - Frank, L. PY - 2000 DA - 2000// TI - When an entire country is a cohort JO - Science VL - 287 UR - https://doi.org/10.1126/science.287.5462.2398 DO - 10.1126/science.287.5462.2398 ID - Frank2000 ER - TY - STD TI - Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549. ID - ref25 ER - TY - JOUR AU - Simon, R. PY - 1986 DA - 1986// TI - Confidence intervals for reporting results of clinical trials JO - Ann Intern Med VL - 105 UR - https://doi.org/10.7326/0003-4819-105-3-429 DO - 10.7326/0003-4819-105-3-429 ID - Simon1986 ER - TY - STD TI - Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL, editors. Comparability and quality control in cancer registration. (IARC Technical Report No. 19). Lyon: IARC (WHO) and IACR; 1994 ID - ref27 ER - TY - STD TI - Sorensen HT, Christensen T, Schlosser HK, et al. Use of medical databases in clinical epidemiology. Department of Clinical Epidemiology, Aarhus, Denmark: SUN-TRYK, Aarhus University; 2009 ID - ref28 ER - TY - JOUR AU - Birch-Johansen, F. AU - Jensen, A. AU - Mortensen, L. PY - 2010 DA - 2010// TI - Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish women JO - Int J Cancer VL - 127 UR - https://doi.org/10.1002/ijc.25411 DO - 10.1002/ijc.25411 ID - Birch-Johansen2010 ER -